Skip to main content
. 2023 Nov 30;17:260–268. doi: 10.1016/j.xjon.2023.10.039

Table 3.

Long-term outcomes

Secondary cancers (n = 26) 23% (6)
Adjuvant therapy (n = 26)
 Chemo XRT 12% (3)
 Chemo 15% (4)
 XRT 4% (1)
 Adjuvant therapy offered and refused 19% (5)
 None 50% (13)
Survival (4 y after)
 Deaths 15% (4)
 Metastatic recurrent cancer 15% (4)

Percentages are based on an “n” of 26 noncarcinoid lung cancers. XRT, Radiotherapy.